JPWO2020205440A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020205440A5 JPWO2020205440A5 JP2021560317A JP2021560317A JPWO2020205440A5 JP WO2020205440 A5 JPWO2020205440 A5 JP WO2020205440A5 JP 2021560317 A JP2021560317 A JP 2021560317A JP 2021560317 A JP2021560317 A JP 2021560317A JP WO2020205440 A5 JPWO2020205440 A5 JP WO2020205440A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- human
- antibody
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826660P | 2019-03-29 | 2019-03-29 | |
| US62/826,660 | 2019-03-29 | ||
| US202062982578P | 2020-02-27 | 2020-02-27 | |
| US62/982,578 | 2020-02-27 | ||
| PCT/US2020/025012 WO2020205440A1 (en) | 2019-03-29 | 2020-03-26 | Methods of reducing large granular lymphocyte and natural killer cell levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022528000A JP2022528000A (ja) | 2022-06-07 |
| JPWO2020205440A5 true JPWO2020205440A5 (ko) | 2023-04-03 |
Family
ID=72666908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560317A Pending JP2022528000A (ja) | 2019-03-29 | 2020-03-26 | 大顆粒リンパ球およびナチュラルキラー細胞レベルを低減する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220185895A1 (ko) |
| EP (1) | EP3946455A4 (ko) |
| JP (1) | JP2022528000A (ko) |
| KR (1) | KR20220032513A (ko) |
| CN (1) | CN113874035A (ko) |
| AU (1) | AU2020251987A1 (ko) |
| CA (1) | CA3135422A1 (ko) |
| IL (1) | IL286720A (ko) |
| SG (1) | SG11202110579WA (ko) |
| WO (1) | WO2020205440A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230104611A (ko) | 2020-09-30 | 2023-07-10 | 드렌 바이오, 인크. | 항-cd94 항체 및 이의 사용 방법 |
| CN116829185A (zh) * | 2020-11-18 | 2023-09-29 | 加利福尼亚大学董事会 | 耗竭抗自然杀伤细胞的单克隆抗体 |
| WO2023183926A1 (en) * | 2022-03-25 | 2023-09-28 | Dren Bio, Inc. | Anti-cd94 antibodies and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1831258B2 (en) * | 2004-12-28 | 2023-06-07 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| WO2007042573A2 (en) * | 2005-10-14 | 2007-04-19 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| NO346945B1 (no) * | 2006-06-30 | 2023-03-13 | Novo Nordisk As | Anti-NKG2A-antistoffer og anvendelser derav |
| MX2010007935A (es) * | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| KR102047248B1 (ko) * | 2011-06-17 | 2019-11-21 | 노보 노르디스크 에이/에스 | 침식성 세포의 선택적 제거 |
| HUE044704T2 (hu) * | 2014-09-16 | 2019-11-28 | Innate Pharma | Kezelési rendek anti-NKG2A ellenanyagok alkalmazásával |
-
2020
- 2020-03-26 AU AU2020251987A patent/AU2020251987A1/en active Pending
- 2020-03-26 JP JP2021560317A patent/JP2022528000A/ja active Pending
- 2020-03-26 SG SG11202110579WA patent/SG11202110579WA/en unknown
- 2020-03-26 WO PCT/US2020/025012 patent/WO2020205440A1/en unknown
- 2020-03-26 US US17/599,481 patent/US20220185895A1/en active Pending
- 2020-03-26 KR KR1020217034728A patent/KR20220032513A/ko unknown
- 2020-03-26 EP EP20785240.1A patent/EP3946455A4/en active Pending
- 2020-03-26 CA CA3135422A patent/CA3135422A1/en active Pending
- 2020-03-26 CN CN202080037754.8A patent/CN113874035A/zh active Pending
-
2021
- 2021-09-26 IL IL286720A patent/IL286720A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7366543B2 (ja) | Ｂｃｍａ結合分子及びその使用方法 | |
| US20210147561A1 (en) | Bispecific antibodies that bind cd123 and cd3 | |
| TWI835141B (zh) | 人類化抗原-結合域及使用方法 | |
| Wu et al. | Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation | |
| JP2014501729A5 (ko) | ||
| PT1758610E (pt) | Métodos para o tratamento de cancro utilizando terapia com il-21 e anticorpos monoclonais | |
| Fang et al. | Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis | |
| Tinubu et al. | Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival. | |
| Nikiforow et al. | Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease | |
| Goldstein et al. | α1β1 integrin+ and regulatory Foxp3+ T cells constitute two functionally distinct human CD4+ T cell subsets oppositely modulated by TNFα blockade | |
| Jakubowski et al. | T cell depletion as an alternative approach for patients 55 years or older undergoing allogeneic stem cell transplantation as curative therapy for hematologic malignancies | |
| Cao et al. | Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation | |
| JPWO2020205440A5 (ko) | ||
| Mansouri et al. | The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy | |
| JPWO2020113194A5 (ko) | ||
| EP1618891A1 (en) | Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor | |
| Dillon et al. | ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome and Systemic Lupus Erythematosus | |
| KR20240032930A (ko) | 사이토카인 방출 증후군을 예측하기 위한 다변량 모델 | |
| Bouhassira et al. | Using gene therapy to manipulate the immune system in the fight against B-cell leukemias | |
| Quintás-Cardama et al. | Targeted therapy for chronic lymphocytic leukemia | |
| Meijer et al. | Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody | |
| Hodgson et al. | LONG TERM IMMUNE RECONSTITUTION FOLLOWING STEM CELL TRANSPLANTATION IN CHRONIC LYMPHOCYTIC LEUKEMIA | |
| OA19653A (en) | BCMA binding molecules and methods of use thereof. | |
| CN114829399A (zh) | 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法 | |
| Goy et al. | Infections in Patients with Hematologic Malignancies Treated with Monoclonal Antineoplastic Therapy |